Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Shree Ganesh Remedies approved its unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2025. Standalone revenue from operations for Q2 FY26 was Rs 3,031.50 lakhs, down from Rs 3,233.19 lakhs in Q2 FY25, while profit after tax fell to Rs 495.57 lakhs from Rs 641.57 lakhs. For H1 FY26, revenue was Rs 5,498.29 lakhs and PAT was Rs 840.51 lakhs, both lower than the previous year. The auditor, Chaudhary Shah & Associates LLP, issued an unqualified review report. The board also accepted the resignation of Mr. Priyam Surendra Shah as Independent Director with immediate effect, citing pre-occupation, with no other material reasons disclosed.
Results show a year-on-year decline in both revenue and profit, which may weigh on short-term sentiment. The exit of a single independent director due to personal pre-occupation is routine and unlikely to materially impact governance or stock price.